Form 4: Prime Medicine Executive Gottesdiener Acquires 100,000 Stock Options

Keith Michael Gottesdiener, a director and officer at Prime Medicine, Inc., acquired 100,000 stock options on February 25, 2024.

Summary

• On February 25, 2024, Keith Michael Gottesdiener, President and Chief Executive Officer of Prime Medicine, Inc., acquired 100,000 stock options.
• The exercise price of these options is $8.32.
• The options vest monthly over a four-year period, starting on February 25, 2024, contingent upon continued service.
• Gottesdiener also holds performance-based options that have not yet vested because the performance criteria have not been met.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard executive compensation practice. The vesting schedule incentivizes long-term commitment.

Positives

• The acquisition of stock options by the CEO could align his interests with those of shareholders, incentivizing him to improve company performance.

Future Outlook

The vesting of the options is contingent upon Gottesdiener's continued service, suggesting an expectation of his continued leadership.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the biotech industry to attract and retain talent.
• Comparing the vesting schedule and exercise price to similar companies like CRISPR Therapeutics or Editas Medicine would provide a benchmark for assessing the competitiveness of this compensation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates